A dynamic nomogram for predicting 28-day mortality in septic shock: a Chinese retrospective cohort study

View article
PeerJ

Introduction

Septic shock belongs to a subclass of sepsis where potential circulatory, cellular, and metabolic abnormalities are related to higher mortality rates than sepsis alone (Guarino et al., 2023). In adults, septic shock can be diagnosed with the clinical standards of hypotension requiring vasopressor treatment to keep average blood pressure (BP) 65 mmHg or higher and having a serum lactate level higher than two mmol/L following adequate fluid resuscitation (Heng et al., 2023). Sepsis and septic shock are associated with high mortality and substantial morbidity. More than 25–30% of patients with sepsis die from the condition, with hospital mortality for septic shock approaching 40–60% (Cecconi et al., 2018; Lakbar et al., 2022). The incidence of sepsis and septic shock has continued to increase (Chiu & Legrand, 2021). Septic shock occurs in more than 230,000 US patients each year, with more than 40,000 US deaths annually (Seymour & Rosengart, 2015). The overall mortality of septic shock in China was 37.3%, which was much higher than that of North America and Europe countries (Liu et al., 2022). Hence, predicting the mortality of septic shock is of great significant to improve survival outcomes in patients with septic shock.

Conventional scoring systems such as the Acute Physiology and Chronic Health Evaluation II (APACHE II) (Choudhuri et al., 2020) and Sepsis Organ Failure Assessment (SOFA) (Devia Jaramillo & Ibáñez Pinilla, 2022) have been used to predict mortality and multi-organ dysfunction. At present, inflammatory molecule osteopontin (OPN) plasma levels at day 1 were identified by Carbone et al. (2020) as a predictor of both 28- and 90-day mortality among patients with septic shock. Hsu, Yang & Tsai (2021) found that lymphocyte to monocyte ratio (LMR) could be used to predict mortality risk in cirrhotic patients with septic shock. A ‘MAVIC’ model incorporating quantitative vasopressor usage was proposed in the American population with septic shock to predict 28-day and 1-year mortality (Vallabhajosyula et al., 2018). Albumin (ALB), base excess, and respiratory rate was used to develop a prediction model for 28-day mortality of severe sepsis and septic shock patients (Seo et al., 2016). For Chinese patients, limited models are established.

In recent years, nomogram has gained widespread utilization in prognosticating various diseases (Yuan et al., 2023; Mei et al., 2022). A nomogram offers several advantages. Firstly, it enables clinicians to visually assess the numerical probability of a patient’s clinical event, thereby helping clinicians make better decisions. Secondly, its user-friendly nature enhances prediction accuracy (Li et al., 2023). Thus, in this study, we intended to develop and validate a dynamic nomogram for predicting 28-day mortality using a contemporary cohort of Chinese patients with septic shock, thereby helping physicians to assess patient survival and optimize personalized treatment strategies for septic shock.

Methods

Study design and population

This retrospective cohort study enrolled patients from the Intensive Care Unit (ICU) of the Second Affiliated Hospital, School of Medicine, Zhejiang University between December 2020 and September 2021. Inclusion criteria: (1) patients diagnosed with septic shock based on The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); (2) patients aged ≥18 years; (3) patients surviving more than 48 h in the ICU; and (4) patients with complete clinical data. Exclusion criteria: (1) patients with autoimmune diseases; (2) patients undergoing organ transplantation or immunosuppressive therapy; (3) patients with advanced malignant tumor; (4) pregnant women; or (5) patients referred or transferred to other hospitals. This study has been approved by the Institutional Review Board of Second Affiliated Hospital, School of Medicine, Zhejiang University (No. 2021(0955)). The need for written informed consent was waived due to retrospective nature of the study.

Outcome variables and follow-up

The primary outcome was 28-day mortality, which was measured from ICU admission to 28 days after the admission. The included patients were followed up by inspection during ICU stay. The follow-up was terminated in October 2021, and the follow-up duration was 28 days.

Data collection

Patient data were extracted from electronic and paper medical records (Seo et al., 2016; Vallabhajosyula et al., 2018): (1) demographic data and physical condition data on admission: sex, age (years), body mass index (BMI, kg/m2), past medical history (hypertension, chronic lung disease, diabetes, chronic kidney disease, heart disease, chronic liver disease, cardiovascular disease, chronic bronchitis), comorbidities (malignancy, coronary artery disease, dyslipidemia, atrial fibrillation, chronic liver disease, chronic obstructive pulmonary disease (COPD), cerebrovascular disease, peripheral vascular disease), infection site (the urinary system, bloodstream, gastrointestinal tract, gallbladder, and others), coma degree (normal state, mild coma, moderate coma, severe coma), systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), heart rate (times/min), respiratory rate (times/min), body temperature (°C), urine volume (mL); (2) laboratory data on admission: neutrophil to lymphocyte ratio (NLR), systemic immune-inflammation index (SII), blood routine (hemoglobin (Hb, g/L), red blood cell (RBC, 1012/L), platelet (PLT, 109/L), hematocrit (HCT, L/L)), blood biochemistry (liver function: alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), total bilirubin (TBIL, µmol/L), albumin (ALB, g/L); renal function: blood urea nitrogen (BUN, mmol/L), creatinine (Cr, µmol/L), uric acid (UA, µmol/L); ion: potassium (mmol/L), sodium (mmol/L), chlorine (mmol/L), calcium (mmol/L); blood glucose (GLU, mmol/L)), inflammatory marker (C-reactive protein (CRP, mg/L), procalcitonin (PCT, µg/L), white blood cell (WBC, 109/L)), blood gas analysis (lactic acid (LAC, mmol/L), blood pH, oxygenation index (PaO2/FiO2), blood oxygen saturation (SaO2, %)), coagulation function (activated partial thromboplastin time (APTT, s), thrombin time (TT, s), prothrombin time (PT, s), fibrinogen (FIB, g/L)), immunological indicator (immunoglobulin G (IgG, mg/dL), complement C3 (g/L), complement C4 (mg/L)); (3) treatment method: fluid resuscitation, vasoactive drugs, glucocorticoids, mechanical ventilation, hemodialysis. Data on length of ICU stay (h) were also collected. Coma degree was assessed by the Glasgow Coma Scale (GCS) from three aspects: eye opening (maximum 4 points), verbal response (maximum 5 points) and motor response (maximum 6 points) (Mehta & Chinthapalli, 2019). The lower the total score, the more serious the coma: 15 points indicated normal state, 13–14 points indicated mild coma, 9–12 points indicated moderate coma, and 3–8 points indicated severe coma.

Construction and validation of prediction nomogram

The included patients were divided into training and testing sets in a ratio of 7:3 using completely random sampling. The prediction model was developed in the training set, and subsequently validated using the testing set. Univariate logistic regression was adopted to screen for potential predictors, and stepwise regression was further used to screen for predictors in the training set. Based on these predictors, a prediction model was constructed for predicting 28-day mortality in patients with septic shock. The prediction model was visualized by constructing a nomogram to estimate the probability of 28-day all-cause mortality in patients diagnosed with septic shock. The receiver operator characteristic curve (ROC) was used to assess the predicting performance of constructed prediction model. Additionally, the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for the model in both the training and testing sets, which were then compared with those for the SOFA and APACHE II systems.

Statistical analysis

Measurement data with normal distribution were described as mean ± standard deviation (Mean ± SD), and the t test was used for inter-group comparisons; measurement data with skewed distribution were shown as median and quartiles (M (Q1, Q3)), and the Wilcoxon rank sum test was applied for comparisons between the two groups. Enumeration data were described using the number of cases and constituent ratio (n (%)), and comparisons between groups were performed using the chi-square test or Fisher’s exact test. Missing values were filled with medians. For between-group difference analysis, patients were divided into survivor and non-survivor groups. As for the association between variables and 28-day all-cause mortality, the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. All statistical tests were two-sided, and P < 0.05 was deemed statistically significant. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was employed for statistical analysis.

Results

Patient characteristics

After excluding 53 patients undergoing lung transplantation and transferred to other hospitals, 304 patients with septic shock were included in this study, with 226 (74.34%) in the survivor group and 78 (25.66%) in the non-survivor group. Figure 1 presents the flow chart of patient selection. The average age and BMI of the included patients were 59.70 ± 15.94 years and 23.01 ± 3.99 kg/m2, respectively. There were 207 (68.09%) male patients, and 97 (31.91%) female patients. These included patients had an average SBP and DBP of 127.10 ± 28.58 and 70.64 ± 16.54 mmHg, respectively. The characteristics of these patients are shown in Table 1. Significant differences were observed in age, chronic lung disease, SBP, DBP, heart rate, atrial fibrillation, cerebrovascular disease, NLR, AST, ALB, BUN, Cr, Cl, CRP, PCT, LAC, oxygenation index (PaO2/FiO2), SaO2, PT, C3, glucocorticoids, mechanical ventilation, and hemodialysis between survivor and non-survivor groups.

Flowchart of patient selection.

Figure 1: Flowchart of patient selection.

Table 1:
Characteristics of the included patients with septic shock.
Variables Total (n = 304) Survivor group (n = 226) 28-day mortality group (n = 78) Statistics P
Sex, n (%) χ2= 1.200 0.273
Male 207 (68.09) 150 (66.37) 57 (73.08)
Female 97 (31.91) 76 (33.63) 21 (26.92)
Age, years, Mean ± SD 59.70 ± 15.94 58.08 ± 16.43 64.38 ± 13.46 t= −3.36 <0.001
BMI, kg/m2, Mean ± SD 23.01 ± 3.99 23.17 ± 3.80 22.56 ± 4.49 t=1.17 0.244
Hypertension, yes, n (%); 119 (39.14) 84 (37.17) 35 (44.87) χ2= 1.445 0.229
Chronic lung disease, yes, n (%); 14 (4.61) 6 (2.65) 8 (10.26) 0.010
Diabetes, yes, n (%); 44 (14.47) 29 (12.83) 15 (19.23) χ2= 1.918 0.166
Chronic kidney disease, yes, n (%); 12 (3.95) 8 (3.54) 4 (5.13) 0.512
Heart disease, yes, n (%); 26 (8.55) 16 (7.08) 10 (12.82) χ2= 2.444 0.118
Chronic liver disease, yes, n (%); 11 (3.62) 7 (3.10) 4 (5.13) 0.482
Cardiovascular disease, yes, n (%); 15 (4.93) 9 (3.98) 6 (7.69) 0.225
Chronic bronchitis, yes, n (%); 4 (1.32) 1 (0.44) 3 (3.85) 0.053
Malignancy, yes, n (%); 46 (15.13) 30 (13.27) 16 (20.51) χ2= 2.366 0.124
Coronary artery disease, yes, n (%); 13 (4.28) 7 (3.10) 6 (7.69) 0.104
Dyslipidemia, yes, n (%); 6 (1.97) 6 (2.65) 0 (0.00) 0.344
Atrial fibrillation, yes, n (%); 20 (6.58) 11 (4.87) 9 (11.54) χ2= 4.199 0.040
Chronic liver disease, yes, n (%); 29 (9.54) 18 (7.96) 11 (14.10) χ2= 2.532 0.112
COPD, yes, n (%); 17 (5.59) 11 (4.87) 6 (7.69) 0.392
Cerebrovascular disease, yes, n (%); 64 (21.05) 38 (16.81) 26 (33.33) χ2= 9.521 0.002
Peripheral vascular disease, yes, (%); 4 (1.32) 4 (1.77) 0 (0.00) 0.576
Infection site, n (%) 0.497
Urinary system 4 (1.32) 4 (1.77) 0 (0.00)
Bloodstream 18 (5.92) 11 (4.87) 7 (8.97)
Gastrointestinal tract 4 (1.32) 3 (1.33) 1 (1.28)
Gallbladder 6 (1.97) 4 (1.77) 2 (2.56)
Others 272 (89.47) 204 (90.27) 68 (87.18)
Coma degree, n (%) 0.100
Normal state 197 (64.80) 155 (68.58) 42 (53.85)
Mild coma 7 (2.30) 5 (2.21) 2 (2.56)
Moderate coma 82 (26.97) 54 (23.89) 28 (35.90)
Severe coma 18 (5.92) 12 (5.31) 6 (7.69)
SBP, mmHg, Mean ± SD 127.10 ± 28.58 129.53 ± 28.10 120.05 ± 28.99 t = 2.55 0.011
DBP, mmHg, Mean ± SD 70.64 ± 16.54 71.88 ± 15.83 67.04 ± 18.08 t = 2.25 0.025
Heart rate, times/min, Mean ± SD 93.76 ± 21.55 92.15 ± 21.08 98.42 ± 22.36 t =  − 2.23 0.027
Respiratory rate, times/min, Mean ± SD 19.54 ± 4.81 19.19 ± 4.33 20.56 ± 5.90 t =  − 1.89 0.062
Body temperature, °C, Mean ± SD 37.27 ± 0.80 37.27 ± 0.75 37.25 ± 0.94 t = 0.17 0.868
Urine volume, mL, M (Q1, Q3) 1050.00 (600.00, 1700.00) 1050.00 (600.00, 1720.00) 1075.00 (490.00, 1590.00) Z =  − 0.129 0.897
NLR, M (Q1, Q3) 13.12 (7.49, 21.60) 11.70 (6.98, 19.22) 17.16 (10.43, 27.81) Z = 3.212 0.001
SII, M (Q1, Q3) 1709.30 (820.62, 3467.08) 1607.12 (775.33, 3126.23) 2322.57 (941.13, 3937.21) Z = 1.503 0.133
Hb, g/L, Mean ± SD 112.65 ± 28.83 113.27 ± 29.69 110.88 ± 26.29 t = 0.63 0.530
RBC, 1012 /L, Mean ± SD 3.48 ± 0.85 3.52 ± 0.88 3.35 ± 0.75 t = 1.56 0.121
PLT, 109 /L, M (Q1, Q3) 147.88 (94.50, 206.50) 156.25 (101.67, 219.00) 133.04 (86.00, 186.80) Z =  − 1.783 0.075
HCT, L/L, Mean ± SD 0.34 ± 0.09 0.34 ± 0.09 0.34 ± 0.08 t = 0.65 0.517
ALT, U/L, M (Q1, Q3) 24.00 (14.00, 42.00) 24.00 (13.00, 39.00) 25.00 (15.00, 55.00) Z = 1.420 0.156
AST, U/L, M (Q1, Q3) 31.00 (20.00, 73.50) 29.34 (19.00, 65.00) 39.00 (26.00, 108.00) Z = 2.959 0.003
TBIL, µmol/L, M (Q1, Q3) 17.17 (11.85, 25.85) 16.65 (11.60, 25.03) 18.05 (12.30, 32.90) Z = 1.162 0.245
ALB, g/L, Mean ± SD 30.45 ± 6.16 31.03 ± 6.07 28.79 ± 6.16 t= 2.79 0.006
BUN, mmol/L, M (Q1, Q3) 7.00 (4.50, 11.00) 6.45 (4.30, 10.30) 8.65 (5.40, 12.30) Z= 2.842 0.004
Cr, µmol/L, M (Q1, Q3) 71.50 (54.50, 108.00) 68.00 (53.00, 97.00) 86.00 (64.00, 131.00) Z = 2.697 0.007
UA, µmol/L, M (Q1, Q3) 252.75 (173.00, 371.00) 242.00 (178.00, 342.00) 282.00 (167.00, 400.00) Z = 0.889 0.374
K, mmol/L, Mean ± SD 3.82 ± 0.71 3.82 ± 0.70 3.83 ± 0.73 t =  − 0.13 0.894
Na, mmol/L, Mean ± SD 137.77 ± 6.27 137.36 ± 5.82 138.96 ± 7.34 t =  − 1.74 0.084
Cl, mmol/L, Mean ± SD 106.95 ± 6.50 106.42 ± 6.35 108.47 ± 6.73 t =  − 2.41 0.017
Ca, mmol/L, Mean ± SD 1.17 ± 0.26 1.17 ± 0.27 1.17 ± 0.22 t = 0.06 0.949
GLU, mmol/L, M (Q1, Q3) 8.00 (6.66, 10.50) 7.90 (6.70, 10.40) 8.40 (6.62, 10.80) Z = 0.601 0.548
CRP, mg/L, M (Q1, Q3) 65.93 (18.95, 144.60) 55.15 (16.80, 118.70) 108.05 (39.40, 200.20) Z = 4.005 <0.001
PCT, µg/L, M (Q1, Q3) 1.34 (0.25, 6.63) 0.95 (0.21, 5.56) 2.69 (0.95, 13.11) Z = 3.845 <0.001
WBC, 109 /L, M (Q1, Q3) 10.38 (7.13, 15.54) 10.38 (7.45, 15.58) 10.38 (6.35, 14.85) Z =  − 0.856 0.392
LAC, mmol/L, M (Q1, Q3) 1.70 (1.20, 2.70) 1.70 (1.10, 2.40) 2.20 (1.40, 4.10) Z = 3.253 0.001
Blood PH, Mean ± SD 7.38 ± 0.10 7.38 ± 0.09 7.36 ± 0.11 t = 1.75 0.084
Oxygenation index (PaO2/FiO2), M (Q1, Q3) 2.39 (1.70, 3.32) 2.64 (1.91, 3.40) 1.84 (1.22, 2.78) Z =  − 4.442 <0.001
SaO2, %, Mean ± SD 97.24 ± 3.53 97.61 ± 2.83 96.16 ± 4.91 t = 2.46 0.016
APTT, s, M (Q1, Q3) 40.15 (34.30, 47.40) 39.35 (34.10, 47.30) 42.15 (35.10, 48.60) Z = 1.640 0.101
TT, s, M (Q1, Q3) 16.50 (15.55, 18.20) 16.50 (15.50, 18.00) 16.65 (15.60, 18.90) Z = 1.268 0.205
PT, s, M (Q1, Q3) 15.10 (13.90, 17.00) 14.90 (13.80, 16.70) 15.60 (14.30, 17.60) Z= 2.483 0.013
FIB, g/L, M (Q1, Q3) 3.73 (2.59, 5.23) 3.59 (2.55, 5.06) 4.44 (2.99, 5.61) Z = 1.718 0.086
IgG, mg/dL, M (Q1, Q3) 9.33 (7.26, 11.80) 9.37 (7.38, 11.80) 9.28 (6.69, 11.80) Z =  − 0.757 0.449
C3, g/L, M (Q1, Q3) 0.79 (0.62, 0.98) 0.82 (0.65, 1.02) 0.72 (0.51, 0.92) Z =  − 2.624 0.009
C4, mg/L, M (Q1, Q3) 187.25 (141.00, 243.50) 191.84 (144.00, 246.00) 168.00 (128.00, 229.00) Z =  − 1.568 0.117
Fluid resuscitation, yes, n (%) 297 (97.70) 221 (97.79) 76 (97.44) 1.000
Vasoactive drugs, yes, n (%) 300 (98.68) 223 (98.67) 77 (98.72) 1.000
Glucocorticoids, yes, n (%) 251 (82.57) 177 (78.32) 74 (94.87) χ2=11.038 <0.001
Mechanical ventilation, yes, n (%) 270 (88.82) 192 (84.96) 78 (100.00) χ2=13.212 <0.001
Hemodialysis, yes, n (%) 124 (40.79) 70 (30.97) 54 (69.23) χ2=35.141 <0.001
Length of ICU stay, h, M (Q1, Q3) 190.00 (90.00, 336.00) 178.00 (74.00, 336.00) 193.00 (96.00, 384.00) Z = 0.424 0.672
DOI: 10.7717/peerj.16723/table-1

Notes:

Fisher’s exact test.

BMI

body mass index

COPD

chronic obstructive pulmonary disease

SBP

systolic blood pressure

DBP

diastolic blood pressure

NLR

neutrophil to lymphocyte ratio

SII

systemic immune-inflammation index

Hb

hemoglobin

RBC

red blood cell

PLT

platelet

HCT

hematocrit

ALT

alanine aminotransferase

AST

aspartate aminotransferase

TBIL

total bilirubin

ALB

albumin

BUN

blood urea nitrogen

Cr

creatinine

UA

uric acid

GLU

blood glucose

CRP

C-reactive protein

PCT

procalcitonin

WBC

white blood cell

LAC

lactic acid

SaO2

blood oxygen saturation

APTT

activated partial thromboplastin time

TT

thrombin time

PT

prothrombin time

FIB

fibrinogen

IgG

immunoglobulin G

ICU

Intensive Care Unit

Predictors for 28-day mortality in septic shock

According to univariate logistic regression, age, chronic lung disease, SBP, DBP, heart rate, atrial fibrillation, cerebrovascular disease, coma degree, TBIL, ALB, Na, Cl, CRP, LAC, oxygenation index (PaO2/FiO2), SaO2, PT, C3, glucocorticoids, and hemodialysis were associated with the risk of 28-day mortality among patients with septic shock (all P <0.05) (Table 2). Further, stepwise regression in the training set identified SBP, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), PT, glucocorticoids, and hemodialysis as the predictors for 28-day mortality of septic shock patients.

Table 2:
Variables associated with 28-day mortality in septic shock patients.
Variables OR (95%CI) P
Sex
Male Ref
Female 0.70 (0.39–1.26) 0.238
Age 1.03 (1.01–1.04) 0.005
BMI 0.97 (0.90–1.03) 0.304
Hypertension, yes; 1.30 (0.77–2.20) 0.334
Chronic lung disease, yes; 4.31 (1.45–12.87) 0.009
Diabetes, yes; 1.53 (0.76–3.09) 0.230
Chronic kidney disease, yes; 1.51 (0.44–5.18) 0.509
Heart disease, yes; 1.99 (0.86–4.59) 0.107
Chronic liver disease, yes; 1.74 (0.49–6.11) 0.389
Cardiovascular disease, yes; 2.07 (0.71–6.01) 0.183
Chronic bronchitis, yes; 9.25 (0.95–90.27) 0.056
Malignancy, yes; 1.74 (0.89–3.41) 0.105
Coronary artery disease, yes; 2.68 (0.87–8.24) 0.085
Dyslipidemia, yes; 0.00 (0.00-Inf) 0.987
Atrial fibrillation, yes; 2.63 (1.04–6.61) 0.040
Chronic liver disease, yes; 1.96 (0.88–4.35) 0.100
COPD, yes; 1.38 (0.46–4.10) 0.566
Cerebrovascular disease, yes; 2.57 (1.43–4.63) 0.002
Peripheral vascular disease, yes; 0.984
Infection site
Urinary system Ref
Bloodstream 0.983
Gastrointestinal tract 0.984
Gallbladder 0.984
Others 0.984
Coma degree
Normal state Ref
Mild coma 1.51 (0.28–8.08) 0.629
Moderate coma 1.89 (1.06–3.36) 0.030
Severe coma 1.89 (0.67–5.34) 0.230
SBP 0.99 (0.98–1.00) 0.020
DBP 0.98 (0.97–1.00) 0.039
Heart rate 1.01 (1.00–1.02) 0.046
Respiratory rate 1.05 (1.00–1.11) 0.076
Body temperature 0.94 (0.68–1.30) 0.693
Urine volume 1.00 (1.00–1.00) 0.503
NLR 1.02 (1.00–1.03) 0.052
SII 1.00 (1.00–1.00) 0.092
Hb 1.00 (0.99–1.01) 0.513
RBC 0.77 (0.56–1.06) 0.106
PLT 1.00 (0.99–1.00) 0.099
HCT 0.39 (0.02–7.49) 0.536
ALT 1.00 (1.00–1.00) 0.678
AST 1.00 (1.00–1.00) 0.231
TBIL 1.01 (1.00–1.02) 0.018
ALB 0.94 (0.90–0.99) 0.010
BUN 1.02 (0.99–1.05) 0.205
Cr 1.00 (1.00–1.00) 0.869
UA 1.00 (1.00–1.00) 0.598
K 1.02 (0.71–1.48) 0.896
Na 1.04 (1.00–1.09) 0.046
Cl 1.05 (1.01–1.10) 0.014
Ca 0.86 (0.30–2.44) 0.780
GLU 1.03 (0.95–1.11) 0.485
CRP 1.01 (1.00–1.01) <0.001
PCT 1.01 (1.00–1.02) 0.114
WBC 0.98 (0.94–1.02) 0.311
LAC 1.14 (1.05–1.23) 0.001
Blood PH 0.10 (0.01–1.35) 0.083
Oxygenation index (PaO2/FiO2) 0.58 (0.44–0.75) <0.001
SaO2 0.90 (0.84–0.97) 0.005
APTT 1.01 (1.00–1.01) 0.264
TT 1.00 (0.99–1.01) 0.599
PT 1.03 (1.00–1.07) 0.036
FIB 1.08 (0.95–1.23) 0.236
IgG 0.98 (0.91–1.05) 0.534
C3 0.29 (0.11–0.78) 0.015
C4 1.00 (1.00–1.00) 0.394
Fluid resuscitation, yes 0.84 (0.16–4.41) 0.834
Vasoactive drugs, yes 1.01 (0.10–9.85) 0.994
Glucocorticoids, yes 4.98 (1.73–14.32) 0.003
Mechanical ventilation, yes 0.980
Hemodialysis, yes 4.83 (2.76–8.45) <0.001
Length of ICU stay 1.00 (1.00–1.00) 0.342
DOI: 10.7717/peerj.16723/table-2

Notes:

BMI

body mass index

COPD

chronic obstructive pulmonary disease

SBP

systolic blood pressure

DBP

diastolic blood pressure

NLR

neutrophil to lymphocyte ratio

SII

systemic immune-inflammation index

Hb

hemoglobin

RBC

red blood cell

PLT

platelet

HCT

hematocrit

ALT

alanine aminotransferase

AST

aspartate aminotransferase

TBIL

total bilirubin

ALB

albumin

BUN

blood urea nitrogen

Cr

creatinine

UA

uric acid

GLU

blood glucose

CRP

C-reactive protein

PCT

procalcitonin

WBC

white blood cell

LAC

lactic acid

SaO2

blood oxygen saturation

APTT

activated partial thromboplastin time

TT

thrombin time

PT

prothrombin time

FIB

fibrinogen

IgG

immunoglobulin G

ICU

Intensive Care Unit

OR

odds ratio

CI

confidence interval

Construction and validation of dynamic nomogram

A prediction model integrating SBP, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), PT, glucocorticoids, and hemodialysis was established to prediction the probability of 28-day all-cause mortality in patients diagnosed with septic shock. As shown in Fig. 2, we plotted a nomogram for visualizing the prediction model. The predicted probability of 28-day mortality was easy to obtain by entering the corresponding values for each predictor. For example, a 60-year-old man had a SBP of 89 mmHg, a Na level of 133.00 mmol/L, an oxygenation index of 2.06, and PT of 19.8 s. He did not have cerebrovascular disease, and was treated with glucocorticoids and hemodialysis. Based on the dynamic nomogram application, the predicted probability of 28-day mortality in this patient was 0.387 (Fig. 3). An online dynamic nomogram is presented for convenient clinical application: https://zhijunxu.shinyapps.io/DynNomapp/.

A nomogram for predicting 28-day mortality for Chinese patients with septic shock.

Figure 2: A nomogram for predicting 28-day mortality for Chinese patients with septic shock.

An example for the application of this developed nomogram.

Figure 3: An example for the application of this developed nomogram.

The ROC curves were utilized in this study to evaluate the predictive ability of the developed prediction model, as demonstrated in Table 3. In the training set, the area under the curve (AUC) of ROC curves for this developed model was 0.829 (95% CI [0.768–0.889]), which were higher compared with SOFA (AUC =0.732, 95% CI [0.649–0.814]) and APACHE II (AUC =0.713, 95% CI [0.634–0.791]), respectively. Similarly, in the testing set, the AUC of the developed model was 0.825 (95% CI [0.728–0.923]), which were also higher than SOFA (AUC =0.707, 95% CI [0.584–0.830]) and APACHE II (AUC =0.718, 95% CI [0.601–0.835]) (Table 3, Fig. 4). In addition, the accuracy, sensitivity, specificity, PPV, and NPV of this model 0.773 (95% CI [0.710–0.827]), 0.783 (95% CI [0.719–0.846]), 0.740 (95% CI [0.618–0.862]), 0.514 (95% CI [0.398–0.629]), 0.906 (95% CI [0.858–0.955]) in the training set, and the accuracy, sensitivity, specificity, PPV, and NPV of this model were 0.747 (95% CI [0.645–0.833]), 0.677 (95% CI [0.563–0.791]), 0.923 (95% CI [0.821–1.000]), 0.533 (95% CI [0.388–0.679]), and 0.957 (95% CI [0.898–1.000]), respectively in the testing set.

Table 3:
Performance of the prediction model in the training and testing sets.
Datasets AUC Accuracy Sensitivity Specificity PPV NPV
Our model
Training set 0.829 (0.768–0.889) 0.773 (0.710–0.827) 0.783 (0.719–0.846) 0.740 (0.618–0.862) 0.514 (0.398–0.629) 0.906 (0.858–0.955)
Testing set 0.825 (0.728–0.923) 0.747 (0.645–0.833) 0.677 (0.563–0.791) 0.923 (0.821–1.000) 0.533 (0.388–0.679) 0.957 (0.898–1.000)
SOFA
Training set 0.732 (0.649–0.814) 0.692 (0.625–0.754) 0.677 (0.605–0.749) 0.740 (0.618–0.862) 0.416 (0.313–0.518) 0.893 (0.839–0.948)
Testing set 0.707 (0.584–0.830) 0.747 (0.645–0.833) 0.862 (0.778–0.946) 0.462 (0.270–0.653) 0.571 (0.360–0.783) 0.800 (0.706–0.894)
APACHE II
Training set 0.713 (0.634–0.791) 0.678 (0.610–0.740) 0.665 (0.592–0.738) 0.720 (0.596–0.844) 0.400 (0.299–0.501) 0.884 (0.827–0.941)
Testing set 0.718 (0.601–0.835) 0.670 (0.564–0.765) 0.631 (0.513–0.748) 0.769 (0.607–0.931) 0.455 (0.307–0.602) 0.872 (0.777–0.968)
DOI: 10.7717/peerj.16723/table-3

Notes:

SOFA

Sepsis Organ Failure Assessment

APACHE II

Acute Physiology and Chronic Health Evaluation II

AUC

area under the receiver operating characteristic curve

PPV

positive predictive value

NPV

negative predictive value

Our model: integrated systolic blood pressure, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), prothrombin time, glucocorticoids, and hemodialysis;

SOFA: a quantitative scoring index that dynamically characterizes sepsis-associated organ dysfunction, encompassing respiratory system, coagulation system, liver function, cardiovascular system, central nervous system, and renal function.

APACHE II: incorporated the age score, acute physiology score, and chronic health status score.

Receiver operator characteristic curves of the prediction model in the training and testing sets.

Figure 4: Receiver operator characteristic curves of the prediction model in the training and testing sets.

Discussion

The current study developed and validated a nomogram to predict 28-day mortality among patients with septic shock in China. SBP, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), PT, glucocorticoids, and hemodialysis were found to be predictors of 28-day mortality in septic shock patients, which were combined to establish the nomogram. By the comparison of ROC curves, this developed model had a good predictive ability than SOFA and APACHE II in 28-day mortality prediction of Chinese patients with septic shock.

Seo et al. (2016) developed a 28-day mortality prediction model (nomogram) for Koreans with severe sepsis and/or septic shock with ALB, base excess, and respiratory rate, which exhibited a validated AUC value of 0.754. In the USA, a MAVIC was proposed including quantitative vasopressor usage, and showed greater ability to predict 28-day death than the APACHE-III and SOFA scores (AUC: 0.73 versus 0.66 and 0.60) in septic shock (Vallabhajosyula et al., 2018). For Chinese patients, a prediction model for the 28-day mortality of individuals with severe sepsis or septic shock was constructed by Wang et al. (2017), whereas there is no specific model for 28-day mortality among septic shock patients. Several studies were carried out in the Chinese population to investigate the predictors of 28-day mortality in septic shock. For instance, the combination of Pcv-aCO(2)/Ca-cvO(2) and lactate clearance rate was reported to be superior to a single parameter in the 28-day death risk of patients with septic shock (Gao, Li & Cao, 2018). Huang et al. (2013) found that in contrast to CRP and WBC, PCT had higher sensitivity for 28-day survival prediction. Further, this study focused on the population with septic shock, and combined multiple parameters to build a prediction model for 28-day mortality. After validation, our model demonstrated good discrimination, which was superior to the SOFA and APACHE II in predicting 28-day mortality. It is worth mentioning that an online dynamic nomogram was constructed (https://zhijunxu.shinyapps.io/DynNomapp/). This online dynamic nomogram is a user-friendly tool for clinicians to visually and quickly assess the risk based on the disease characteristics of their patients. Our nomogram has the capability to effectively identify patients with septic shock at high risk of 28-day poor outcome. In real-world clinical settings, clinicians could utilize a nomogram to easily get the numerical probability of 28-day mortality of patients with septic shock based on patients’ clinical indicators, and then early personalized intervention may be conducted to improve prognoses in septic shock.

SBP, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), PT, glucocorticoids, and hemodialysis were utilized herein for prediction model development. Of these predictors, cerebrovascular disease contributed the most to the model, followed by glucocorticoids, and hemodialysis. In a previous study including patients with sepsis or septic shock, cerebrovascular disease was identified as a predictor for shorter survival (Schmidt et al., 2020). It is common to use glucocorticoids in critically ill patients (Gibbison et al., 2017). Glucocorticoids are used as immunosuppressants (Veterans Administration Systemic Sepsis Cooperative Study Group, 1987), and applied as non-catecholamine vasoconstrictors for patients who do not respond to high-dose vasopressors (so-called low-dose hydrocortisone (<400 mg/day)) in sepsis (Annane et al., 2010; Gordon et al., 2014). Patients with glucocorticoid deficiency related to their critical illness can also be treated with glucocorticoids (Marik et al., 2008; Molenaar et al., 2011). In this paper, we included glucocorticoid use as a predictor of 28-day mortality for septic shock patients, which enriched the role of glucocorticoids in septic shock. A previous review reported that long-term low-dose glucocorticoid treatment reduced the risk of 28-day mortality by 24% in septic shock (Boyer et al., 2006). Hemodialysis was also regarded as predictive of 28-day mortality in septic shock. Suh, Kim & Kim (2021) identified hemodialysis as a risk factor for 30-day mortality in adult candidemia patients. A study by Clark et al. (2016) found that chronic dialysis patients with septic shock had similar in-hospital mortality to those non-dialysis patients. More investigations are required to verify the predictive value of hemodialysis.

This study proposed a prediction model of 28-day mortality in Chinese patients with septic shock for the first time, which was easy to use. Overall, the model exhibited a greater prediction performance than the SOFA and APACHE II. In clinical practice, clinicians can make early intervention decisions in reference to this user-friendly model, so as to improve prognoses. Some limitations should be noted. First, the study was retrospective and single-centered, which may result in limited generalization. Second, the model was constructed based on the baseline data of indicators, without considering the impact of changes in indicators on mortality.

Conclusion

SBP, cerebrovascular disease, Na, oxygenation index (PaO2/FiO2), PT, glucocorticoids, and hemodialysis were found to be predictors of 28-day mortality in septic shock patients, which were combined to establish the dynamic nomogram (https://zhijunxu.shinyapps.io/DynNomapp/). This dynamic nomogram was validated to have better discrimination, accuracy, specificity, and NPV than the SOFA and APACHE II in 28-day mortality prediction of Chinese patients with septic shock. In the future, we will conduct external validation at other centers to verify actual clinical effectiveness of the developed nomogram.

Supplemental Information

Original dataset

DOI: 10.7717/peerj.16723/supp-1
  Visitors   Views   Downloads